Harbor Capital Advisors, Inc. Arvinas, Inc. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$36.38 - $52.31 $151,268 - $217,504	4,158 Added 22.89%	22,325 $922,000
Q4 2023 Jan 08, 2024	BUY	$14.19 - $42.33 $17,581 - $52,446	1,239 Added 7.32%	18,167 $747,000
Q3 2023 Oct 20, 2023	BUY	$19.64 - $28.21 $48,196 - $69,227	2,454 Added 16.95%	16,928 $332,000
Q2 2023 Jul 11, 2023	BUY	$21.73 - $31.43 $29,139 - $42,147	1,341 Added 10.21%	14,474 $359,000
Q1 2023 Apr 26, 2023	BUY	$26.15 - $37.26 $5,386 - $7,675	206 Added 1.59%	13,133 $358,000

Q4 2022 Jan 20, 2023	SELL	$32.47 - $57.24 $8,994 - $15,855	-277 Reduced 2.1%	12,927 $0
Q3 2022 Oct 28, 2022	SELL	$41.87 - $57.99 $60,334 - $83,563	-1,441 Reduced 9.84%	13,204 $587,000
Q2 2022 Jul 26, 2022	SELL	$36.01 - $74.24 $66,402 - $136,898	-1,844 Reduced 11.18%	14,645 $616,000
Q1 2022 Apr 28, 2022	SELL	$60.27 - $81.57 $189,488 - $256,456	-3,144 Reduced 16.01%	16,489 $1.11 Million
Q4 2021 Feb 04, 2022	BUY	$65.85 - $96.21 $1.29 Million - $1.89 Million	19,633 New	19,633 $1.61 Million

234

64.9M

119K

94.2K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.42B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.